Episode 15: Why implement NGS for gene therapies biosafety testing?

Jean-François Brepson, CEO of PathoQuest

Episode 14: Why implement NGS for biosafety testing for cell therapies?

Jean-François Brepson, CEO of PathoQuest

Episode 13: At which phase of development should NGS be implemented in biosafety testing

Jean-François Brepson, CEO of PathoQuest

Episode 12: What is the latest regulatory trend for NGS in biosafety testing ?

Jean-François Brepson, CEO of PathoQuest

Episode 11: Why use NGS for bulk harvest testing?

Amina Cherif Louazani, Viral Safety and Regulatory Affairs Manager at PathoQuest

Episode 10:How NGS assays are validated?

Sebastien Renouf, Chief Pharmaceutical Officer at PathoQuest

Episode 9: Can NGS detect all viruses?

Sandrine Moreira, Head of Bioinformatics at PathoQuest

Episode 8: Do I really need to perform a comparability run between NGS and classical biosafety tests?

Colette Côté, US General Manager, Chief Scientific and Portfolio Officer of PathoQuest

Episode 7: What are the regulatory tools to support NGS testing in your IND/IMPD?

Stanley Prince, CCO of PathoQuest

Episode 6: How does NGS reduce time to market in Biopharma?

Colette Côté, US General Manager, Chief Scientific and Portfolio Officer of PathoQuest

Episode 5: How does NGS fit within my modality?

Stanley Prince, CCO of PathoQuest

Episode 4: Is NGS testing in biopharma a possible alternative to animal virus testing?

Jean-François Brepson, CEO of PathoQuest

Episode 3: Is NGS testing in biopharma approved by regulators and industry?

Jean-François Brepson, CEO of PathoQuest

Episode 2: Is NGS testing in biopharma validated to GMP standards?

Jean-François Brepson, CEO of PathoQuest

Episode 1: Why adopt NGS for Quality Control in Biopharma?

Jean-François Brepson, CEO of PathoQuest